A laboratory in Lanarkshire has started harvesting stem cells from children’s teeth.
It’s hoped the cells can be used in a cure if the children develop a disease later in life.
The American company BioEden will cryogenically store the cells in return for a monthly fee.
Relatively few stem cell therapies are currently in use but hundreds more are being researched.
Happy Thanksgiving! This year during your holiday meal, share what you are thankful for and think about how to pay it forward on #GivingTuesday.
We are working hard to treat age-related diseases so that we all get to enjoy more wonderful days together like this. We need your help to do it.
Speculation about what order rejuvenation biotechnologies will arrive.
The first rejuvenation therapies to work well enough to merit the name will be based on the SENS vision: that aging is at root caused by a few classes of accumulated cell and tissue damage, and biotechnologies that either repair that damage or render it irrelevant will as a result produce rejuvenation. Until very recently, no medical technology could achieve this goal, and few research groups were even aiming for that outcome. We are in the midst of a grand transition, however, in which the research and development community is finally turning its attention to the causes of aging, understanding that this is the only way to effectively treat and cure age-related disease. Age-related diseases are age-related precisely because they are caused by the same processes of damage that cause aging: the only distinctions between aging and disease are the names given to various collections of symptoms. All of frailty, disease, weakness, pain, and suffering in aging is the result of accumulated damage at the level of cells and protein machinery inside those cells. Once the medical community becomes firmly set on the goal of repairing that damage, we’ll be well on the way to controlling and managing aging as a chronic condition — preventing it from causing harm to the patient by periodically repairing and removing its causes before they rise to the level of producing symptoms and dysfunction. The therapies of the future will be very different from the therapies of the past.
The full rejuvenation toolkit of the next few decades will consist of a range of different treatments, each targeting a different type of molecular damage in cells and tissues. In this post, I’ll take a look at the likely order of arrival of some of these therapies, based on what is presently going on in research, funding, and for-profit development. This is an update to a similar post written four years ago, now become somewhat dated given recent advances in the field. Circumstances change, and considerable progress has been made in some lines of research and development.
1) Clearance of Senescent Cells
It didn’t take much of a crystal ball four years ago to put senescent cell clearance in first place, the most likely therapy to arrive first. All of the pieces of the puzzle were largely in place at that time: the demonstration of benefits in mice; potential means of clearance; interested research groups. Only comparatively minor details needed filling in. Four years later no crystal ball is required at all, given that Everon Biosciences, Oisin Biotechnologies, SIWA Therapeutics, and UNITY Biotechnology are all forging ahead with various different approaches to the selective destruction of senescent cells. No doubt many groups within established Big Pharma entities are also taking a stab at this, more quietly, and with less press attention. UNITY Biotechnology has raised more than $100 million to date, demonstrating that there is broad enthusiasm for this approach to the treatment of aging and age-related disease.
Our brains have a basic algorithm that enables us to not just recognize a traditional Thanksgiving meal, but the intelligence to ponder the broader implications of a bountiful harvest as well as good family and friends.
“A relatively simple mathematical logic underlies our complex brain computations,” said Dr. Joe Z. Tsien, neuroscientist at the Medical College of Georgia at Augusta University, co-director of the Augusta University Brain and Behavior Discovery Institute and Georgia Research Alliance Eminent Scholar in Cognitive and Systems Neurobiology.
In a cross-domain study directed by professor Peter Carmeliet (VIB — KU Leuven), researchers discovered unexpected cells in the protective membranes that enclose the brain, the so called meninges. These ‘neural progenitors’ — or stem cells that differentiate into different kinds of neurons — are produced during embryonic development. These findings show that the neural progenitors found in the meninges produce new neurons after birth — highlighting the importance of meningeal tissue as well as these cells’ potential in the development of new therapies for brain damage or neurodegeneration. A paper highlighting the results was published in the leading scientific journal Cell Stem Cell.
Scientists’ understanding of brain plasticity, or the ability of the brain to grow, develop, recover from injuries and adapt to changing conditions throughout our lives, has been greatly broadened in recent years. Before the discoveries of the last few decades, neurologists once thought that the brain became ‘static’ after childhood. This dogma has changed, with researchers finding more and more evidence that the brain is capable of healing and regenerating in adulthood, thanks to the presence of stem cells. However, neuronal stem cells were generally believed to only reside within the brain tissue, not in the membranes surrounding it.
The meninges: unappreciated no more: Believed in the past to serve a mainly protective function to dampen mechanical shocks, the meninges have been historically underappreciated by science as having neurological importance in its own right. The data gathered by the team challenges the current idea that neural precursors — or stem cells that give rise to neurons — can only be found inside actual brain tissue.
BENGALURU: After working for five years, a team of three from department of Biosciences and Bioengineering (BSBE) at Indian Institute of Technology (IIT), Bombay and IITB-Monash Research Academy has designed smart amyloid based hydrogels that are able to guide stem cell to differentiate to neuron and successfully transplanted these stem cells in the brain of Parkinson’s disease (PD) animal models with unique amyloid hydrogels.
Researchers at Stanford University have demonstrated that it’s possible to send text messages using nothing more than an Arduino and household chemicals.
New biomarkers for aging is good news for researchers!
“Given the high volume of data being generated in the life sciences, there is a huge need for tools that make sense of that data. As such, this new method will have widespread applications in unraveling the molecular basis of age-related diseases and in revealing biomarkers that can be used in research and in clinical settings. In addition, tools that help reduce the complexity of biology and identify important players in disease processes are vital not only to better understand the underlying mechanisms of age-related disease but also to facilitate a personalized medicine approach. The future of medicine is in targeting diseases in a more specific and personalized fashion to improve clinical outcomes, and tools like iPANDA are essential for this emerging paradigm,” said João Pedro de Magalhães, PhD, a trustee of the Biogerontology Research Foundation.
The algorithm, iPANDA, applies deep learning algorithms to complex gene expression data sets and signal pathway activation data for the purposes of analysis and integration, and their proof of concept article demonstrates that the system is capable of significantly reducing noise and dimensionality of transcriptomic data sets and of identifying patient-specific pathway signatures associated with breast cancer patients that characterize their response to Toxicol-based neoadjuvant therapy.
The system represents a substantially new approach to the analysis of microarray data sets, especially as it pertains to data obtained from multiple sources, and appears to be more scalable and robust than other current approaches to the analysis of transcriptomic, metabolomic and signalomic data obtained from different sources. The system also has applications in rapid biomarker development and drug discovery, discrimination between distinct biological and clinical conditions, and the identification of functional pathways relevant to disease diagnosis and treatment, and ultimately in the development of personalized treatments for age-related diseases.